July 5, 2022 Research Bulletin
Volume 3, Issue 13
Featured Funding Opportunities
- 08/10/22 - Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)
- 08/25/22 - Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 – Clinical Trial Not Allowed)
- 09/08/22 - NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
- 09/15/22 - Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required)
- 10/05/22 - Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
- 10/05/22 - Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
- 10/16/22 - Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
- 10/16/22 - Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
- 10/17/22 - Network for Personalization of Diagnostic Tests for Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD) in Older Adults with Multiple Chronic Conditions (MCCs) (U24 Clinical Trial Optional)
- 10/21/22 - Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed)
- 10/25/22 - Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
- 10/25/22 - Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
- 11/14/22 - Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
- 11/15/22 - Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)
- 11/18/22 -Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)
NIH Funding Announcements
NIH funding opportunities and notices are presented weekly. Please see the current and past updates below.
Limited Funding Opportunities
Please take a moment to visit and bookmark the newly launched website featuring limited funding opportunities.
To submit a proposal for these opportunities:
Interested candidates must send a one-page summary of their research proposal and their biosketch in pdf format via the Limited Submission Portal.
LOC of the People: Widening the Path: Community Collections Grants to Organizations
- Materials due to Internal Review Committee: July 13, 2022
- Sponsor Deadline: August 1, 2022
NEA Our Town
- Materials due to Internal Review Committee: July 13, 2022
- Concept Outlines due to sponsor: August 4, 2022
LOC of the People: Widening the Path: Connecting Communities Digital Initiative - Libraries, Archives and Museums
- Materials due to Internal Review Committee: August 9, 2022
- Sponsor Deadline: September 30, 2022
Searle Scholars Program
- Materials due to Internal Review Committee: August 9, 2022
- Sponsor Deadline: September 30, 2022
Special Announcements
The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. A list of eligible proteins is provided below and in the FOA and all are members of druggable protein families that have a known association with a rare disease.
The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied.
For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.
Applications for the 2022 Gates Grubstake Fund awards are now being accepted. The Gates Center for Regenerative Medicine and CU Innovations annually make multiple awards of up to $350,000 to investigators who are researching and developing regenerative medicine related technologies, including therapeutics, diagnostics, devices, manufacturing, and platforms.
Applications are due on Wednesday, August 31, 2022.
To apply, and for further information, contact the Gates Center’s Entrepreneur in Residence and CU Innovations Director of Licensing Heather Callahan.
Register for the next quarterly Community Engagement Forum hosted by CCTSI and ACCORDS — Understanding and Appreciating the Capacities of the Community: How Partnerships Ensure More Equitable Research Design, Conduct, and Dissemination
Date: Wednesday, July 27, 2022
Time: 12:00-1:00 PM MT Zoom
For more information, recordings, or to learn about other upcoming educational events contact Jordan Crawford.
Peter J. Culshaw Family Junior Investigator Award in Type 1 Diabetes Research 2022 Request for Applications
The Peter J. Culshaw Family Junior Investigator Award is intended to support a promising young investigator developing novel ideas in type 1 diabetes.
This program will provide $50,000 a year for two years (renewable for a third year if adequate progress is demonstrated) to support development of research ideas and preparation to compete for external funding.
Letter of Intent due: July 15, 2022
Application submission due: August 1, 2022
For application questions please contact Alejandro Cervantes-Koerselman.
Metabolic Imaging Workshop
We are pleased to announce the first “Metabolic Imaging Workshop” hosted by the Colorado Nutrition and Obesity Research Center (NORC) and the Colorado Clinical and Translational Science Institute (CCTSI).
This workshop will provide a broad overview on state-of-the-art metabolic imaging modalities and protocols including PET/CT, PET/MRI, MRI/MRS, QCT, DXA, and ultrasound.
July 11-12, 2022
For questions, please contact the workshop directors, Dr. Ed Melanson and Dr. Natalie Serkova.
Wednesday, July 13, 2022 from 4 – 6 pm
Customer discovery is challenging. This session will focus on creating good questions for use during a customer discovery session.
This session will review the I-Corps@NCATS training program, discuss Business Canvas and Innovation Within tools and will focus on developing your question database.
More more information contact Claire McDonald.
This bulletin is distributed on the 1st & 3rd Tuesday of the month for the CU Anschutz Research Community.
Past Research Bulletins can be found here.
Please click here if you wish to be added to this distribution.